Kura Oncology to Report Second Quarter 2018 Financial Results
July 30, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
July 02, 2018 16:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
June 28, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Commencement of Public Offering of Common Stock
June 27, 2018 16:01 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 27, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial
June 20, 2018 07:30 ET
|
Kura Oncology, Inc.
– John Farnam appointed to newly created position of Chief Operating Officer – – Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join as Vice Presidents of Clinical Development – –...
Kura Oncology to Present at JMP Securities Life Sciences Conference
June 14, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
OncoDNA announces screening collaboration with Kura Oncology
May 22, 2018 07:00 ET
|
Kura Oncology, Inc.
- OncoDNA to support patient enrolment for Kura Oncology’s Phase II trial of tipifarnib- Agreement demonstrates OncoDNA’s biopharma partnership strategy GOSSELIES, Belgium, May 22, 2018 (GLOBE...
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 08, 2018 16:05 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 – – Data from multiple Phase 2 trials of...
Kura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
May 03, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
May 02, 2018 07:30 ET
|
Kura Oncology, Inc.
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for...